Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:EXAS News 20 November 2025 - 2 February 2026

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott shares closed up 0.97% at $125.78 Tuesday, holding steady after hours. Exact Sciences, which Abbott plans to acquire for up to $23 billion, disclosed accelerated executive payouts to address “golden parachute” tax rules. Investors are tracking Abbott’s Volt device rollout and a recent FDA alert on its diabetes sensors. U.S. stocks ended lower in thin holiday trading.
31 December 2025
·
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below the agreed $105 per‑share cash buyout price. Exact Sciences Investor Relations+1 Below is a deep dive into the latest news, earnings, analyst forecasts, and key risks around Exact Sciences stock as of December 1, 2025. Exact Sciences Stock Today: Trading
1 December 2025
··
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday, 25 November 2025, Exact Sciences stock is trading around $101 per share, hovering just below its all‑time and 52‑week high near $102.ChartMill+1 That puts EXAS: At this point, EXAS is behaving less like a typical growth stock and more like a merger‑arbitrage trade: most of the upside is capped by the announced cash offer, while the remaining discount compensates investors
25 November 2025
··
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist. With shares hovering around $101 this afternoon and a cash offer on the table at $105 per share, Exact Sciences has effectively shifted from a high‑growth story to a merger‑arbitrage situation — but there’s still plenty happening around the name on November 24, 2025. Exact Sciences Investor Relations+1 Key takeaways for EXAS stock on November 24, 2025 Exact
24 November 2025
··
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2 The move marks Abbott’s largest acquisition in nearly a decade and one of the biggest healthcare deals of 2025, instantly positioning the company as a heavyweight in cancer screening and precision oncology diagnostics — markets it has largely approached from the sidelines until now. Reuters+1 As of mid‑afternoon trading, ABT
20 November 2025
··
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will
20 November 2025
··

Stock Market Today

NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

8 February 2026
NXP Semiconductors shares closed up 1% at $224.32 Friday after subsidiaries amended a $3 billion revolving credit deal with Barclays, maturing in 2031. The PHLX semiconductor index surged 5.7% as chip stocks rallied on AI spending signals from Amazon and Alphabet. NXP’s gain lagged peers like Monolithic Power, which rose 6.4%. Investors await U.S. jobs and inflation data next week.
Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

8 February 2026
Cambricon Technologies shares closed at 1,036.99 yuan in Shanghai on Friday, down 2.02%, with volume at about 8 million shares. The stock has fallen roughly 16.5% since Feb. 2 after sharp declines earlier in the week. Investors await the company’s next earnings report, due March 13, for confirmation of its forecasted profit turnaround. Cambricon is valued at about 437.28 billion yuan.
Go toTop